Drug intelligence / Profile preview

durvalumab + tremelimumab + Yttrium-90 radioembolisation

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intra-arterial

Overview

durvalumab + tremelimumab + Yttrium-90 radioembolisation is a combination therapy regimen being evaluated by The University of Hong Kong for the treatment of metastatic hepatocellular carcinoma (HCC). The regimen consists of two immune checkpoint inhibitors developed by AstraZeneca—durvalumab (an anti-PD-L1 monoclonal antibody) and tremelimumab (an anti-CTLA-4 monoclonal antibody)—alongside Yttrium-90 (Y90) radioembolisation, a form of selective internal radiation therapy (SIRT). This triple combination aims to leverage the synergistic potential of dual checkpoint blockade and localized radiation to induce an abscopal effect, enhancing systemic anti-tumor immunity in patients with previously untreated advanced disease. The clinical trial (NCT05809869) utilizes a priming dose of immunotherapy followed by Y90 administration to optimize the immune-priming effects of radiation.

Brand names: ImfinziImjudo
Other names: durvalumab-The University of Hong Kong-hepatocellular carcinomadurvalumab + tremelimumab + Y90Durvalumab, Tremelimumab and Radioembolisation in Metastatic HCC

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on durvalumab + tremelimumab + Yttrium-90 radioembolisation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab + tremelimumab + Yttrium-90 radioembolisation.

Explore the full profile